039. INTERFERON-ALFA USED TO TREAT A CHALLENGING CASE OF REFRACTORY PAEDIATRIC BEHÇETS DISEASE WITH SIGHT-THREATENING UVEITIS

Canakinumab for Childhood Sight-threatening Refractory Uveitis: A Case Series.

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease

Behçet's disease (BD) involves multisystem vasculitis of unknown origin. Ocular manifestations of BD mostly include bilateral panuveitis and retinal vasculitis, which are very challenging to treat. Interferon alfa-2a (IFN) has been recently introduced for treating refractory Behçet uveitis, mainly in Germany and Turkey. Nonetheless, there is so far no consensus about the ideal treatment regimen...

Steroid refractory CD4+ T cells in patients with sight-threatening uveitis.

PURPOSE A discrete subpopulation of steroid refractory (SR) CD4(+) T cells has recently been identified in patients with SR ulcerative colitis (UC). The purpose of this study was to test whether this subpopulation is also present in patients with clinically defined SR uveitis. As interleukin (IL)-2 experimentally mediates the SR phenotype, the combined effects of dexamethasone (Dex) and a range...

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

BACKGROUND Behçet's disease is a multisystem vasculitis of unknown origin. Standard treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly posterior uveitis with retinal vasculitis, leads to blindness in 20-50% of the involved eyes within 5 years. The efficacy of interferon alfa-2a was studied in patients with sight threatening posterior uveitis or retinal vasc...

CLINICAL SCIENCE Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis

Background: Behçet’s disease is a multisystem vasculitis of unknown origin. Standard treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly posterior uveitis with retinal vasculitis, leads to blindness in 20–50% of the involved eyes within 5 years. The efficacy of interferon alfa-2a was studied in patients with sight threatening posterior uveitis or retinal vas...